Project Grant HT94252410973
Award Date
10/1/24
Completion Date
9/30/27
Dollars Obligated
$464K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Athens, GA 30602, USA
Similar Awards
The Department of Defense's Defense Health Agency awarded a $685,778 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the University of Georgia Research Foundation, Inc. This federal grant, titled "Endoplasmic Reticulum-Targeted Radiodynamic Therapy for the Treatment of Lung Cancer," will fund research from July 2024 through July 2027. The University of Georgia Research Foundation is the prime recipient and will collaborate with Emory...
The Department of the Army Medical Command awarded a $564,698.00 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Texas A&M Engineering Experiment Station (Tees) to develop "Engineered Therapeutic Extracellular Vesicles to Resolve Pyridostigmine Bromide-Induced Enteric Neuroinflammation in Gulf War Illness." The grant, with a performance period from November 1, 2024 to October 31, 2027, will support advanced biomedical research...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program provides $158,254.00 to the University of Illinois to support a research project titled "DUAL CRE/LOX AND LENTIVIRAL CRISPR/CAS9 SYSTEM FOR PRECISE IN VIVO DISSECTION OF GBM AND MICROENVIRONMENT INTERACTION." The project aims to advance scientific understanding and treatment of glioblastoma (GBM) by developing innovative genetic technologies for in...
The Defense Health Agency awarded a $1,535,920.00 Project Grant to the Translational Genomics Research Institute (TGen) under the Military Medical Research and Development program (CFDA 12.420). The grant supports TGen's research on genomic structural mutations associated with telomere dysfunction in glioblastoma cells and patients. The 4-year project will utilize advanced genomic analysis and sequencing techniques to gain insights into the molecular mechanisms driving glioblastoma, a highly...
The U.S. Defense Health Agency awarded a $636,883 Project Grant to the University of California, Los Angeles (UCLA) to conduct research on "Targeting the EGFR Signaling Network in Glioblastoma". This award, funded through the Military Medical Research and Development program (CFDA 12.420), will support UCLA's work to investigate new approaches for treating glioblastoma, an aggressive type of brain cancer, by targeting the EGFR signaling network. The research will take place at UCLA's...
Emory University was awarded a $159,929 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will fund whole-genome structural variation and CpG methylation analyses through long-read sequencing from April 1, 2023 to March 31, 2025. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public health care through innovative medical...
Georgetown University received a $971,537 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on April 1, 2024, will support research to target cellular senescence and prevent post-traumatic epilepsy. The project will be conducted at Georgetown's facility in Washington, D.C. and is scheduled for completion by March 31, 2027. The Military Medical Research and Development program funds a...
This $159,900 federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program supports preclinical research on brain metastases in lung cancer. The award will fund studies at the University of Illinois to develop and evaluate novel drug efficacy and resistance models for advancing the treatment of brain metastases, a significant challenge in lung cancer management. Spanning one year from August 2024 to August...
The Project Grant award of $352,000.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) will support the Sloan-Kettering Institute for Cancer Research in augmenting the in vivo efficacy of a novel lanosterol synthase inhibitor for the treatment of glioblastoma. The award, with a performance period from September 1, 2025 to August 31, 2027, will enable Sloan-Kettering to conduct advanced biomedical research focused on transforming healthcare for...
This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $713,277 to Boston University Medical Campus to conduct research on the translational impact of genetic susceptibility to complex toxic exposures on blood-brain barrier function and age-related neurological outcomes in Gulf War Illness. The award will support the project from September 1, 2024 through August 31, 2027. As part of this...